No major mutation observed in SARS-COV 2, no indication vaccine strategy would be hindered: Study
Sunday, 18 October 2020 A pan-India study by the Department of Biotechnology suggests that A2a strain of SARS-CoV-2, which is the prominent novel coronavirus subtype found in the country, has not undergone any major mutation since June and there is no indication that the vaccine or diagnostics strategy would be hindered.
Routine testing patients for COVID-19 before major surgery could reduce the risk of respiratory complications and save lives, a new study revealed. Researchers working together around the world found that using a nasal swab test to confirm that asymptomatic patient was not infected with SARS-CoV-2 was associated with a lower rate of postoperative complications. The main benefit was seen before major surgery and areas with a higher rate of COVID-19. Swab testing gave an opportunity for surgeons to identify asymptomatic infected patients and postpone their operation, avoiding the severe risk of COVID-19 complications after surgery. Routine testing also helped to prevent cross-infection from patients with no symptoms to other elective surgical patients upon admission to hospital. The COVIDSurg toolkit will support individual hospitals, regions, and countries during a major global reorganisation of surgical services during the pandemic and beyond.
A new open source, a cloud-based tool called IDseq makes it possible to rapidly detect, identify, and track emerging pathogens such as SARS-CoV-2. This tool can identify pathogens before there is an available complete genome sequence; thus, it can be used for current infectious disease outbreaks and also for emerging ones. This will substantially aid in preventing future pandemics. The study was published in the journalGigaScience. The coronavirus pandemic demonstrates the importance of global infectious disease monitoring. Finding the cause of an infectious disease outbreak is challenging, especially if it stems from a previously unknown pathogen. IDseq, an open-source, cloud-based metagenomic analysis platform, identifies both novel and existing disease-causing pathogens from a given sample - be it a human, animal, or parasite - to provide an actionable report of what is happening on the ground in labs and clinics anywhere in the world. The new user-friendly IDseq software is open source and freely available to the global health community, reducing the barrier of entry to metagenomics.
Addressing a joint press conference in the national capital on November 12, Union Finance Minister Nirmala Sitharaman spoke on COVID Suraksha Mission.She said, "Rs 900 crore provided for COVID Suraksha Mission for research and development of the Indian COVID vaccine to the Department of Biotechnology."
Coronavirus antibodies might exist in a person's blood at least three months after they were infected, according to a study in Science Immunology. Newsmax Also reported by •NaturalNews.com •News24 •FT.com